Jackie is Chief Executive Officer and Managing Director of Starpharma Holdings Ltd (ASX:SPL) as ASX300 Company. She has 25 years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Hospira).
She was appointed Chief Executive Officer of Starpharma in July 2006 and under her leadership the company has signed a number of transformational commercial deals and developed several new and valuable applications for the Company proprietary technology in areas including pharmaceuticals and Agrochemicals. During Jackie's tenure as CEO, Starpharma has raised more than A$50 million in equity and significantly strengthened its institutional shareholder base, attracting investment from major local and global funds. During her time as CEO the Company's market capitalization has increased several-fold and in 2011, Starpharma joined the ASX 300. Jackie has an MBA from Melbourne Business School where as dux she was the recipient of the prestigious Clemenger Medal. She holds first class honours degrees in Science (pharmacology) and Veterinary Science from the University of Melbourne. Jackie is also a Graduate of the Australian Institute of Company Directors. In addition to her role as CEO of Starpharma, Jackie currently serves on the Board of Melbourne Business School where she is a member of the Remuneration and Nominations Committee. She also sits on the Investment Committee of Carnegie Venture Capital's Innovation Fund and in 2014 was appointed as one of 3 Industry representatives on the Federal Government's Economic Review Panel for Victoria. She is also a past member of the Federal Government's Pharmaceutical Industry Working Group, the Victorian Innovation Economy Advisory Board, Federal Biotechnology Advisory Council and the Geelong Grammar School Council.